Nimbus Discovery To Present Data Showing That Selective ACC Inhibitors Dramatically Impact Tumor Growth In Pre-Clinical Models At American Association for Cancer Research Annual Meeting 2014
4/2/2014 9:37:38 AM
Nimbus Discovery LLC, a biotechnology company discovering novel medicines against exciting but previously inaccessible drug targets, today announced that data on its Acetyl CoA Carboxylase (ACC) program will be presented at the 105th Annual Meeting of the American Association for Cancer Research. Nimbus will present data in two abstracts showing activity with ND-646 and ND-654 in non-small cell lung cancer (NSCLC) and hepatocellular carcinoma (HCC) respectively. The conference will take place on April 5-9th at the Diego Convention Center, San Diego, California.
Help employers find you! Check out all the jobs and post your resume.
comments powered by